Drug Profile
CC 42344
Alternative Names: CC-42344Latest Information Update: 03 Apr 2024
Price :
$50
*
At a glance
- Originator Cocrystal Pharma Inc
- Class Antivirals; Small molecules
- Mechanism of Action Influenza virus PB2 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Influenza A virus infections
- Preclinical Influenza A virus H1N1 subtype
Most Recent Events
- 28 Mar 2024 Cocrystal Pharma plans a phase I trial for Influenza A virus infections (In Volunteers) in Australia (Inhalation) in 2024
- 22 Mar 2024 Cocrystal Pharma plans a phase IIb trial in Influenza A virus infections in USA
- 19 Mar 2024 Cocrystal Pharma plans to file IND application to the US FDA for CC 42344 in Influenza A virus infections